Form 4: Provectus CEO Converts Promissory Note to Preferred Stock

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note (the '2024 Note') into Series D-1 Convertible Preferred Stock.
• The conversion occurred on August 22, 2025, at a price of $2.862 per share of Series D-1 Preferred Stock.
• The 2024 Note, with outstanding principal and interest of $100,000, automatically converted into 37,760 shares of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.
• Following this transaction, Edward Pershing beneficially owns 37,760 shares of Series D-1 Convertible Preferred Stock and a total of 2,352,367 shares of Common Stock (including those underlying the preferred stock).

Sentiment

Score: 6

Explanation: The filing reports a pre-planned, automatic conversion of debt to equity by an insider. This is a neutral event in terms of immediate news, as it was expected. It reduces company debt but introduces future dilution, balancing out the sentiment.

Positives

• The conversion of the promissory note into preferred stock reduces the company's outstanding debt, potentially improving its balance sheet liquidity.
• The transaction was part of the Issuer's 2024 Financing, indicating a structured approach to capital management.

Negatives

• The conversion of preferred stock into common stock on June 20, 2026, will result in dilution for existing common shareholders.

Risks

• Future conversion of Series D-1 Preferred Stock into common stock will dilute the ownership percentage of existing common shareholders.

Future Outlook

The Series D-1 Convertible Preferred Stock held by Edward Pershing is scheduled for automatic conversion into common stock on June 20, 2026, unless converted earlier.

Industry Context

This transaction is a routine insider filing for a biotechnology company, reflecting a pre-planned conversion of debt to equity, which is a common financing mechanism in the industry to manage capital structure and reduce interest burdens.

Comparison to Industry Standards

• The use of convertible notes and preferred stock is a standard financing tool for growth-stage biotechnology companies like Provectus, allowing them to raise capital with deferred equity dilution.
• The 1:10 conversion ratio from preferred to common stock is within typical ranges for such instruments, designed to provide a premium to preferred shareholders while managing common stock price impact.

Related Party Transactions

• The transaction involves Edward Pershing, the CEO and a Director of Provectus Biopharmaceuticals, converting a promissory note issued by the company, making it a related party transaction.

Stakeholder Impact

• Shareholders: The conversion of preferred stock into common stock in the future will lead to dilution of existing common shareholders' ownership percentage.
• Creditors: The conversion of the promissory note reduces the company's outstanding debt, potentially improving its credit profile.

Next Steps

• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Form 4, Insider Transaction, Convertible Note, Preferred Stock, Debt Conversion, Equity Financing, Biotechnology